Stephen A Udem

US Patent:

6716431, Apr 6, 2004

Filed:

Dec 7, 2001

Appl. No.:

10/048540

Inventors:

Peng Tian - Monroe NY
Timothy J. Zamb - Nyack NY
Stephen A. Udem - New York NY

Assignee:

Wyeth Holdings Corporation - Madison NJ

International Classification:

A61K 3915

US Classification:

4242151, 4352351, 435236, 4353201, 435 693, 536 2372

Abstract:

The nonstructural protein 4 (NSP4) in the SA11 ATCC rotavirus strain has a histidine at amino acid position 47. This substituted form is more cytotoxic than the NSP4 of the Australia rotavirus strain, which has an asparagine at amino acid position 47. The histidine at amino acid position 47 is mutagenized to another amino acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity. NSP4 having a glutamic acid at amino acid position 48 is more cytotoxic than NSP4 having a lysine at amino acid position 48. The lysine at amino acid position 48 is mutagenized to another amino acid other than glutamic acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity.

US Patent:

7485415, Feb 3, 2009

Filed:

Feb 19, 2003

Appl. No.:

10/505818

Inventors:

Deborah A. Buonagurio - Rye NY, US
Alice F. Georgiu - Montgomery NY, US
Robert A. Lerch - New Hempstead NY, US
Bruce B. Mason - Downington PA, US
Shridhara C. Murthy - Ann Arbor MI, US
Ruth S. Rappaport - Strafford PA, US
Mohinder S. Sidhu - New City NY, US
Stephen A. Udem - New York NY, US
Timothy J. Zamb - Nyack NJ, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q 1/70
C12N 15/46
C12N 15/63
C12N 1/21
C12N 5/10
A61K 39/15

US Classification:

435 5, 4353201, 435 693, 435325, 4352523, 43525411, 4242151

Abstract:

Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus: human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.

US Patent:

7541038, Jun 2, 2009

Filed:

Jun 2, 2004

Appl. No.:

10/559429

Inventors:

Gerald Raul Kovacs - Potomac MD, US
Xiaoyan Mo - Boxborough MA, US
Nikolaos Vasilakis - Galveston TX, US
Sangeeta Bhargava - Potomac MD, US
Timothy Joseph Zamb - Nyack NY, US
Stephen Alexander Udem - New York NY, US

Assignee:

Wyeth Holdings Corporation - Madison NJ

International Classification:

A61K 39/155
C12N 15/86

US Classification:

4241991, 4242111, 4353201, 4352351

Abstract:

Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.

US Patent:

8287878, Oct 16, 2012

Filed:

Apr 5, 2005

Appl. No.:

11/547236

Inventors:

David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Warwick NY, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/12
C12N 7/01

US Classification:

4241991, 4352351, 4353201

Abstract:

The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.

US Patent:

8647638, Feb 11, 2014

Filed:

Aug 31, 2012

Appl. No.:

13/600289

Inventors:

David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Atlanta GA, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/205
A61K 39/12
C12N 7/01
C12N 15/63

US Classification:

4242241, 4241991, 4352351, 4353201

Abstract:

The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.

US Patent:

7361496, Apr 22, 2008

Filed:

Aug 2, 2000

Appl. No.:

10/048384

Inventors:

David K. Clarke - Chester NY, US
J. Erik Johnson - Verona NJ, US
Mohinderjit S. Sidhu - Scotch Plains NJ, US
Stephen A. Udem - New York NY, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12N 7/00

US Classification:

4352351, 435 691, 4353201, 435239, 435455, 435456, 435471, 435476

Abstract:

This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.

US Patent:

20030129729, Jul 10, 2003

Filed:

Oct 1, 2002

Appl. No.:

10/261961

Inventors:

Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
Gerald Kovacs - Morristown NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12N007/02
C07H021/04
C12N007/00
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/239000, 435/235100, 536/023720, 435/320100

Abstract:

This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV). One method for producing a recombinant virus from the Order Mononegavirales comprises (a) in at least one host cell, conducting transfection of a rescue composition which comprises (i) a transcription vector comprising an isolated nucleic acid molecule which comprises polynucleotide sequence encoding a genome or antigenome of a nonsegmented, negative-sense, single stranded RNA virus of the Order Mononegavirales and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication; in a host cell under conditions sufficient to permit the co-expression of these vectors and the production of the recombinant virus; (b) heating the transfected rescue composition to an effective heat shock temperature under conditions sufficient to increase the recovery of the recombinant virus; and optionally, (c) harvesting the resulting recombinant virus.

US Patent:

20050089985, Apr 28, 2005

Filed:

Jun 22, 2001

Appl. No.:

10/312052

Inventors:

Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - New City NY, US
Pramila Walpita - Basking Ridge NJ, US
Gerald Kovacs - Ridgewood NJ, US
Stephen Udem - New York NY, US

International Classification:

C12N007/00
C12N015/86

US Classification:

435235100, 435456000

Abstract:

This invention relates to a method for recombinantly producing via rescue canine distemper virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the canine distemper virus as an attenuated and/or infectious viruses. The recombinant viruses can be prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and rearrangements, in the genome can be obtained.